Inflammatory Bowel Disease CD19+ B Cells

Inflammatory Bowel Disease CD19+ B Cells for Mucosal Immunology Research

Inflammatory Bowel Disease (IBD) CD19+ B Cells are cryopreserved from peripheral blood of IRB-consented adult donors diagnosed with IBD. These CD19+ B cells reflect disease-associated humoral alterations and support studies of mucosal immunity, antibody responses, and B cell activation.

Ulcerative Colitis or Crohn’s Disease?

“IBD” covers two conditions that differ in anatomy, histology, and — importantly for B cell work — serology. Specifying the subtype usually matters more than the cell count:

• Ulcerative colitis — continuous mucosal inflammation limited to the colon. Characteristically pANCA-positive with an IgG1-dominant mucosal response
• Crohn’s disease — patchy transmural inflammation anywhere from mouth to anus, with granulomas. Characteristically ASCA-positive with an IgG2-dominant response

That pANCA/ASCA and IgG1/IgG2 divergence is the reason a mixed IBD cohort can mask an effect that a subtype-specific cohort would reveal. If your protocol genuinely calls for the broad category — method development, or a marker expected to be shared — we can assemble a mixed set with each donor’s specific diagnosis annotated.

B Cells in IBD

IBD is an immune-mediated inflammatory disease driven by a dysregulated mucosal response to intestinal microbiota in genetically susceptible individuals. It is not classically autoimmune — no single pathogenic autoantigen defines it — and the B cell story is largely about loss of tolerance to commensal flora rather than to self:

• Anti-microbiota antibody responses — ASCA, anti-flagellin, anti-OmpC and related specificities
• Plasma cell expansion in the lamina propria and altered circulating plasmablast frequency in active disease
• Reduced regulatory B cell function
• Serological markers that aid UC/Crohn’s discrimination but are not themselves pathogenic
• Lymphocyte trafficking — vedolizumab targets α4β7 integrin, measurably altering circulating populations in treated donors

Donor Stratification Available

• IBD subtype — UC, Crohn’s, or IBD-unclassified, annotated per donor
• Disease activity — Mayo/UCEIS for UC, HBI/CDAI for Crohn’s, where recorded
• Disease location and extent
• Serology — pANCA and ASCA where tested
• Inflammatory markers — CRP and faecal calprotectin where available
• Treatment status — 5-ASA, thiopurine, anti-TNF, anti-integrin, anti-IL-23, or JAK inhibitor
• Matched healthy controls available

Product Features

• Research Use Only (RUO), CD19+ enriched B cells
• Isolated from clinically diagnosed IBD donors
• High viability and enrichment
• Cryopreserved in CryoStor® CS10 media
• Processed within 24 hours of collection
• Flow cytometry purity and viability data per lot
• Ethically sourced with IRB approval and HIPAA compliance

De-identified Donor Data

• Confirmed diagnosis of inflammatory bowel disease, including subtype
• Demographics: age, sex assigned at birth, race/ethnicity
• Self-reported clinical history and medication use

Applications

• B cell phenotyping and function in IBD
• Mucosal humoral immunity and anti-microbiota antibody studies
• pANCA/ASCA serology and differential diagnosis research
• BCR repertoire sequencing and IgG subclass analysis
• Comparative UC vs Crohn’s studies
• Biologic mechanism-of-action research
• Disease mechanism studies and biomarker identification
• Preclinical immunotherapy development

Other IBD Specimen Types

Matched material is available as IBD CD56+ NK cells, IBD leukopak, and IBD bulk plasma. Subtype-specific cohorts are available for ulcerative colitis and Crohn’s disease.

Compliance and Quality Assurance

• IRB-approved collection and 21 CFR Part 11-compliant e-consent
• Standardized processing and quality protocols
• HIPAA-compliant data handling

Ordering & Customization

Inflammatory Bowel Disease CD19+ B Cells are offered in standard or custom aliquot sizes. For pricing, regulatory documentation, or international support, contact learnmore@sanguinebio.com. For the full range, see our human CD19+ B cells collection.